Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Oct 04, 2021 11:52am
215 Views
Post# 33960951

RE:We are still in the pre-clinical stage.

RE:We are still in the pre-clinical stage.
Rarbar99 wrote:

The FDA processing is far more rigorous and strict than it is here in Canada. In the eyes of the FDA, we are still in the pre-clinical stage. Not even stage 1. 


it's important for everyone to know this. 



I don't think it's that simple.
With all the data that's been collected - and all the data that is being collected - the FDA will be clear about what they still want to see.
It all depends on what ATE finds and the direction(s) they'd like to pursue.

Likely - a smaller P2 will be required before a P3 in one aspect.
But, I also see an opportunity for a P2/3 in a different aspect - should ATE chase it.
Again, still more complex than that as other avenues may persent themselves.

We need to wait for ATE findings and the path forward - then maybe we can better pin down what kind of development company we are.

Right now ... we really only know we are "on pause."
<< Previous
Bullboard Posts
Next >>